Open access
48
Views
5
CrossRef citations to date
0
Altmetric
Review
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
Yijun Xu1 Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA;2 Tianjin Chest Hospital, Tianjin, People’s Republic of China
, Vivianne W Ding1 Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
, Hong Zhang2 Tianjin Chest Hospital, Tianjin, People’s Republic of China
, Xun Zhang2 Tianjin Chest Hospital, Tianjin, People’s Republic of China
, David Jablons1 Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
& Biao He1 Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USACorrespondence[email protected]
Pages 807-816
|
Published online: 24 May 2016
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.